Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its journey towards going public after receiving regulatory approval [1][2]. Group 1: Company Overview - Deshi Biotechnology focuses on chromosome karyotype analysis, a classic method for diagnosing major diseases related to chromosomal abnormalities, which include birth defects, infertility, and hematological malignancies [1]. - The traditional karyotype analysis method relies heavily on manual operations, resulting in an average accuracy rate of only about 50% and a reporting cycle of approximately 30 days [1]. Group 2: Market Position and Innovation - The automated karyotype analysis market is dominated by international giants like Carl Zeiss and Leica, which hold over 95% of the market share [2]. - In response to the significant market demand and the lack of domestic equipment, Deshi Biotechnology has pursued an independent innovation path, developing intelligent devices and systems based on the iMedImage platform model [2]. - The company has created a highly integrated automated cell laboratory pipeline that covers four key stages of chromosome karyotype analysis: cell harvesting, slide preparation, image acquisition, and intelligent analysis, achieving full-process automation and standardization [2]. - By 2024, Deshi Biotechnology is projected to capture a market share of 30.6% in China's chromosome karyotype analysis sector, surpassing international competitors and marking a leap forward for domestic manufacturers [2].

Core Points - Company announced that five products have received EU CE certification, including a film dyeing integrated machine, an automatic slide maker, and three consumable products [1] - The certification allows these products to be sold in the EU and European Economic Area (EEA) markets, facilitating entry into other international markets that recognize or reference EU standards [1] - The certificates for the certified products are valid from July 2025 and are long-term [1] Market Expansion - The actual sales performance of the certified products will depend on market promotion effectiveness, brand influence, and actual market demand, indicating significant uncertainty [1] - The company stated that obtaining the EU In Vitro Diagnostic Medical Device Regulation (IVDR) certification will aid in entering other international markets that recognize EU standards, further broadening the overseas application scenarios for these products [1] - The company has already obtained market access qualifications in multiple countries and regions, including Japan, the EU, Ukraine, Ecuador, and Vietnam, and plans to accelerate the expansion of its overseas access footprint [1]